Missak Haigentz, MD, discussed the implications and next steps of the ADRIATIC study in patients with limited-stage small ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...

The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, ...

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and ...

Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease ...

A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line ...

Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

During a Case-Based Roundtable® event,  Michael R. Bishop, MD, moderated a discussion on monitoring and treatment of chronic ...